-The Hindu As a sun-swept country, India should have been a pioneer in the use of solar power with a photovoltaic panel on every roof. Good policy can help make up for lost time. Solar is the most secure of all energy sources, since it is abundantly available in India. With crippling electricity shortages, the price of electricity traded internally touched Rs. 7 a unit for base loads and Rs. 8.50 during...
More »SEARCH RESULT
Total Matching Records found : 798
Reliance Industries unit fined Rs. 11 crore for insider trading
-Reuters Mumbai: The Securities and Exchange Board of India (Sebi) has fined a unit of energy conglomerate Reliance Industries Ltd Rs. 11 crore over a 2007 insider trading case. The company, Reliance Petroinvestments Ltd, has 45 days to pay the fine, the Sebi said in its ruling published late on Thursday. The regulator said Reliance Petroinvestments made a profit of Rs. 3.83 crore through several trades between February and March 2007 that were...
More »FDI in retail is a boon, says Supreme Court-J Venkatesan
-The Hindu In a relief to the Centre, the Supreme Court on Wednesday upheld the government's proposal to allow foreign direct investment (FDI) in multi-brand retail trade (MBRT) saying the move did not suffer from any unconstitutionality, illegality, arbitrariness or irrationality. A three-judge bench of Justices R.M. Lodha, Madan B. Lokur and Kurian Joseph said "consumer is king and if that is the philosophy working behind the policy then what is wrong...
More »Strong medicine for poor countries-Nayanima Basu
-The Business Standard The Novartis verdict by the Supreme Court emphasised the importance of flexibilities in drug patent laws, in contrast to Western countries which are seeking TRIPS-plus hardening through free-trade agreements As curtains on the six-year-long legal tussle with Swiss drug giant Novartis AG finally came down earlier this month, the Indian government did not waste a second in hailing the Indian patent law which it said was in "full...
More »In the ‘pharmacy of the world’ -PT Jyothi Datta
-The Hindu Business Line From maker of versions of drugs, India's pharmaceutical industry has turned a top innovator Twenty years ago, Ranbaxy was a home-spun drug-maker. The Indian Patents Act allowed companies to make chemically-similar versions of innovative drugs. Visionaries in the pharmaceutical sector, like Parvinder Singh (Ranbaxy's key architect and member of its promoter family) and Anji Reddy (founder of Dr Reddy's Laboratories), were alive. And the pharmaceutical industry did not have...
More »
